After Leqembi Approval, US FDA In No Rush To Declare Amyloid A Validated Surrogate Endpoint

 
• By Sue Sutter
  
Clock in sand
US FDA likely to take its time in making a validation decision about amyloid reduction as a surrogate endpoint. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards